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Summary
— The synthesis of 2,4-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,3,5-triazine 6a and 2,4-
bis[4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]-1,3,5-triazine 6b in 3 steps from either 4-
bromobenzamidine or 4-(carbamoyl)benzamidine is reported. The synthesis of 4,6-bis[4-(4,5-
dihydro-1H-imidazol-2-yl)phenyl]-2-dimethylamino-1,3,5-triazine 9a and 4,6-bis[4-(1,4,5,6-
tetrahydropyrimidin-2-yl)phenyl]-2-dimethylamino-1,3,5-triazine 9b in 2 steps from 1,4-
dicyanobenzene is also described. The compounds 6b and 9b bind strongly to DNA model
sequences and inhibit topoisomerase II from 2 microbial sources. Compounds 6a and 9a bind to
both DNA and RNA model sequences whereas 6b and 9b essentially do not bind to the RNA
model.
Keywords
triazine; diaryldiamidine; DNA; RNA; topoisomerase II
Introduction
Previous investigations in our laboratory have found that dicationic diaryldiamidines are
active antiprotozoan agents [1] and exhibit strong binding to DNA [2–4]. Pentamidine and
analogs have been found to be effective in treatment of Pneumocystic carinii pneumonia
(PCP) and are useful in controlling AIDS-related PCP [5–7]. Relationships between DNA
binding, inhibition of DNA-dependent enzymes, diamidine molecular shape and in vivo anti-
PCP activity are beginning to emerge [8]. Typically, these dicationic molecules bind to
DNA by selectively interacting with AT-rich regions of the minor groove. The
complementarity of the curvature of the dicationic molecules with that of the minor groove
of DNA has been considered an important determinant in the interaction of such groove
binders with DNA [9–11]. Recently Cory et al have expanded upon the isohelicity paradigm
of Cain, Dickerson, Lown and others by developing a method to estimate the radius of
curvature of dicationic groove-binding molecules [8]. These workers found that pentamidine
and analogs with radius of curvature values of between 10 and 100 Å strongly bind to DNA
whereas analogs with smaller or larger values interact more weakly. However, it is
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important to note that the precise mode of binding of these dicationic molecules to DNA can
be highly sensitive to structure [2–4]. Berenil and stilbamidine bind in the minor groove of
DNA at sites which have 3 or more consecutive AT base pairs [12,13]. DAPI, 2-[4′-guanyl-
phenyl]-6-guanylindole, which has been known for some time to bind in the minor groove of
DNA at AT sites, has recently been found to intercalate at GC sites [3]. The nucleic acid
binding properties of a series of 2,5-diphenylfuran dications were found to range in
interaction with DNA from AT selective minor groove binding, to classical intercalation at
GC sites, to threading intercalation at GC sites [4]. The specific binding mode appears to
depend upon the intrinsic nature of the cationic groups [4]. Although pentamidine and
analogs and the 2,5-diphenylfuran dications have comparable radius of curvature values, the
furan series can form a more extensive planar array and is thereby potentially capable of
intercalation. Consequently, bis-benzamidines linked by planar rings (eg furans) appear
prone to exhibit multiple binding modes to DNA.
We report here the synthesis of dicationic 2,4-diaryl-1,3,5-triazines, which have radius of
curvature values in the range found by Cory et al and are favorable for strong binding to the
DNA minor groove [14]. These molecules contain the triazine ring as the link between the
bis-benzamidines, which is more hydrophilic than the furan link mentioned previously.
Therefore, the dicationic triazines can be expected to exhibit different adsorption and
distribution characteristics.
Chemistry
The synthesis of the key precursor 3 of the desired dicationic 2,4-bis-diaryl-1,3,5-triazines
was achieved by 2 similar approaches (see scheme 1). Fusion of 4-bromobenzamidine
benzenesulfonate 1 and formamidine hydrochloride at 190°C for 16 h gave 2,4-bis-(4-
bromophenyl)-1,3,5-triazine 2 in good yield [15]. Conversion of the bis-bromo compound 2
into the corresponding bis-nitrile 3 was also achieved in reasonable yield by the action of
copper(I) cyanide in quinoline at reflux temperature [16]. The bis-nitrile 3 was also obtained
from a 2-step process beginning with the fusion of 4-(carbamoyl)benzamidine 4 with
formamidine hydrochloride to form 2,4-bis[(4-carbamoyl)phenyl]-1,3,5-triazine 5 [15]. The
bis-amide 5 was readily dehydrated by the action of phosphorus oxychloride to give the bis-
nitrile 3 in good yield [17]. Both the imidazoline 6a and the tetrahydropyrimidine 6b were
obtained by reaction of the bis-nitrile 3 in the presence of hydrogen sulfide with the
appropriate diamine [18]. In the case of the reaction of 3 with ethylenediamine a small
amount of the mono-substitution product, 4-(4-cyanophenyl)-2-[4-(4,5-dihydro-1H-
imidazol-2-yl)phenyl]-1,3,5-tri-azine 6c was also obtained. The synthesis of 4,6-(4-
cyanophenyl)-2-dimethylamino-1,3,5-triazine 8 was accomplished in a 1-step process by the
reaction of 1,4-dicyanobenzene 7 and 1,1-dimethylguanidine in the presence of sodium
hydride (see scheme 2) [19]. The dicationic triazines 9a and 9b were obtained by fusion of
the bis-nitrile 8 with ethylenediamine and 1,3-propanediamine hydrochloride, respectively
[20].
Biological results and discussion
The results for the biological evaluation of dicationic diaryl triazines 6a, 6b, 9a and 9b are
found in table I. The interaction of the dicationic triazines with DNA was assessed by
measuring the increase in thermal melting temperature (ΔTm) on complex formation with
poly dA·dT [21]. As can be seen from table I, the 2-dimethylaminotriazines 9a and 9b give
larger ΔTm values than the unsubstituted triazines 6a and 6b. In both sets of triazines the
tetrahydropyrimidine compounds 6b and 9b exhibit larger ΔTm values than their
imidazoline counterparts 6a and 9a. The greater ΔTm values for both sets being compared
may be attributable to the theoretically greater van-der-Waals interactions of the respective
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triazines within the DNA minor groove. As expected, the mono cation 6c interacts only very
weakly with DNA. The imidazoline derivatives 6a and 9a exhibit significant binding to the
RNA model poly A·U, whereas 6b and 9b only weakly interact. The stronger binding of the
dicationic imidazolines relative to the tetrahydropyrimidines with RNA is consistent with
the previously reported study which suggested that such molecules bind to RNA by
intercalation [21]. The dicationic triazines were evaluated against HIV-1 in a previously
described cell culture screen [22], since 6a and 9a showed significant binding to our RNA
model. Significant anti-HIV activity was noted for the stronger RNA binding molecules 6a
and 9a, but significant levels of cell toxicity were also noted suggesting that these
compounds may not be selective inhibitors against HIV-1 in culture. Since topoisomerase
inhibition has been implicated in the mode of antimicrobial action of other diamidines the
triazines were also evaluated against topoisomerase II isolated from 2 organisms [23,24].
The 2 dicationic compounds 6b and 9b, which exhibit the significantly stronger binding to
DNA, also show the greater inhibition of Giardia lamblia topoisomerase II, a similar trend
is noted for inhibition of topoisomerase II isolated from P carinii. Three of the dicationic
triazines 6a, 9a and 9b were evaluated in vivo against P carinii pneumonia using the
immunosuppressed rat model [25]. Unlike many other dicationic diaryldiamidines, the
triazine compounds exhibited severe toxicity to the animals and further synthetic
investigation of the diaryltriazine system was discontinued.
Experimental protocols
2,4-Bis(4-bromophenyl)-1,3,5-triazine 2
4-Bromobenzamidine benzenesulfonate [26] (7.32 g, 0.02 mol) and formamidine
hydrochloride (2.15 g, 0.03 mol) were mixed and heated for 16 h in an oil-bath at 190°C
After cooling, the mixture was poured into water, washed with water, dried and crystallized
from acetone to give the product. Yield, 3.37 g (84%), mp 199°C. 1H-NMR (CDCl3, TMS),
δ 7.68 (d, 4H, J = 8.3 Hz), 8.48 (d, 4H, J = 8.3 Hz), 9.23 (s, 1H). 13C-NMR (CDCl3, TMS),
δ 128.1, 130.4, 132.1, 134.3, 166.9, 170.7. IR (KBr): ν 1589, 1576, 1543, 1512, 1415, 1071,
1011, 801 cm−1. MS, m/z: 389, 391, 393 (peaks in the molecular ion region).
2,4-Bis(4-cyanophenyl)-1,3,5-triazine 3
A mixture of 2,4-bis(4-bromophenyl)-1,3,5-triazine (3.17 g, 0.008 mol) and copper(I)
cyanide (1.8 g, 0.02 mol) in freshly distilled quinoline (30 mL) was refluxed for 2 h. After
cooling the reaction mixture was poured into ether (100 mL), washed with ether and water,
and then extracted in a Soxhlet apparatus using acetone as a solvent. The crude product was
crystallized from pyridine, washed with ether and recrystallized from acetone. Yield 1.49 g
(65%), mp 263°C. Anal calc C17H9N5: C, 72.07; H, 3.20; N, 24.73; found: C, 71.79; H,
3.28; N, 24.64. 1H-NMR (DMSO-d6), δ 8.06 (d, 4H, J = 8.3 Hz), 8.71 (d, 4H, J = 8.3 Hz),
9,54 (s, 1H). 13C-NMR (DMSO-d6), δ 115.1, 117.9, 129.0, 132.7, 138.6, 167.4, 169.3. IR
(KBr): ν 2224, 1544, 1515, 1422, 1315, 1016, 812 cm−1. MS, m/z: 283 (M+).
2,4-Bis[(4-carbamoyl)phenyl]-1,3,5-triazine 5
The title compound was prepared from commercially available 4-amidinobenzamide
hydrochloride (24 g, 0.120 mol) and formamidine hydrochloride (12.6 g, 0.156 mol) in
essentially the same way as described for 2,4-bis(4-bromophenyl)-1,3,5-triazine. The crude
product (18.7 g, 98%) was extracted overnight with chloroform in a Soxhlet apparatus. The
colorless crystals were filtered (2 g, mp 285°C). The insoluble product remaining in the
thimble (16.5 g) was used in the next step. 1H-NMR (DMSO-d6), δ 7.48 (br s, 2H), 8.05 (d,
4H, J = 8.3 Hz), 8.10 (br s, 2H), 8.49 (d, 4H, J = 8.3 Hz), 9.43 (s, 1H). 13C-NMR (DMSO-
d6), δ 128.0, 128.2, 136.9, 138.3, 166.6,167.1, 169.3. IR (KBr): ν 3408, 3194,1660, 1574,
1514, 1440, 1397, 1313,818 cm−1.
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Formation of 3 by dehydration of 2,4-bis[(4-carbamoyl)phenyl]-1,3,5-triazine
2,4-Bis[(4-carbamoyl)phenyl]-1,3,5-triazine (16.5 g, 0.05 mol) was placed in phosphorus
oxychloride (90 mL) and refluxed for 3 h. The excess phosphorus oxychloride was removed
under diminished pressure and the residue carefully decomposed with ice. The solid was
filtered off, washed with water, dried and extracted with acetone in a Soxhlet device to
afford 2,4-bis(4-cyanophenyl)-1,3,5-triazine (12.11 g, 83%). Spectral and analytical data
were given above.
2,4-Bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-1,3,5-triazine dihydrochloride dihydrate 6a
A solution of 2,4-bis[(4-cyanophenyl)]-1,3,5-triazine (0.5 g, 0.002 mol) and 1,2-
diaminoethane (5 mL, 0.08 mol) in 1,2-dimethoxyethane (25 mL) was saturated with
hydrogen sulfide and then refluxed overnight. Progress of the reaction was monitored by
TLC (CHCl3/CH3OH/NH4OH, 11:4:1, v/v/v). After cooling, the precipitate was collected
and extracted overnight with acetone in a Soxhlet apparatus. The acetone solution was
concentrated and crystals of 4-(4-cyanophenyl)-2-[4-(4,5-dihydro-1H-imidazol-2-
yl)phenyl]-1,3,5-triazine 6c separated (109 mg, 19%), mp 271°C. Anal calc
C19H14N6·0.25H2O: C, 68.97; H, 4.41; N, 25.40; found: C, 68.75; H, 4.39; N, 25.25. 1H-
NMR (DMSO-d6, TMS), δ 3.73 (s, 4H), 8.06 (d, 2H, J = 8.3 Hz), 8.07 (d, 2H, J = 8.3 Hz),
8.63 (d, 2H, J = 8.3 Hz), 8.73 (d, 2H, J = 8.3 Hz), 9.49 (s, 1H). 13C-NMR (DMSO-d6,
TMS),δ 48.8, 114.9, 117.9, 127.6, 128.3, 128.9, 132.6, 133.5, 136.4, 138.8, 162.9, 167.1,
169.1, 170.0. IR (KBr): ν 3197, 2924, 2230, 1605, 1573, 1525, 1410, 818 cm−1. MS, m/z:
326 (M+).
The residue from the thimble was refluxed with dimethylformamide and filtered hot, washed
with water and acetone (mp > 300°C). The hydrochloride had mp > 300°C (0.44 g, 52%).
Anal calc C21H19N7·2HCl·2H2O: C, 52.39; H, 5.24; N, 20.37; found: C, 52.65; H, 5.29; N,
20.50. 1H-NMR (D2O, (CH3)3SiCH2CH2COONa), δ 4.14 (s, 8H), 7.97 (d, 4H, J = 8.3 Hz),
8.61 (d, 4H, J = 8.3 Hz), 9.38 (s, 1H). 13C-NMR (D2O, (CH3)3SiCH2CH2COONa), δ 47.6,
128.9, 131.5, 132.4, 141.6, 168.5, 169.9, 173.2. IR (KBr): ν 3344, 1616, 1567, 1540, 1510,
1422, 1289, 820 cm−1. MS (free base) m/z: 369 (M+).
2,4-Bis[4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]-1,3,5-triazine dihydrochloride dihydrate
6b
This compound was prepared from the dinitrile (0.5 g) in essentially the same way as
described above for the imidazolinyl derivative, but traces of a monocyano intermediate
were not isolated. (TLC, CHCl3/CH3OH/NH4OH, 7:5:2, v/v/v). The hydrochloride has mp >
300°C (0.60 g, 67%). Anal calc C23H23N7·2HCl·2H2O: C, 54.55; H, 5.77; N, 19.36; found:
C, 54.63; H, 5.85; N, 19.29. 1H-NMR (DMSO-d6, TMS), δ 2.04 (t, 4H, J = 4.88 Hz), 3.55 (t,
8H, J = 5.38 Hz), 8.04 (d, 4H, J = 8.30 Hz), 8.78 (d, 4H, J = 8.30 Hz), 9.56 (s, 1H), 10.27 (s,
4H). 13C-NMR (DMSO-d6), δ 17.4, 38.6, 128.3, 128.7, 132.2, 138.7, 158.5, 167.4, 169.6. IR
(KBr): ν 3446, 3160, 3022, 1647, 1541, 1422, 1373, 1314, 817, 740 cm−1. MS (free base),
m/z: 397 (M+). Caution: an excess of 1,2-diaminoethane causes decomposition of the
triazine ring and 1,4-bis[2-(4,5-dihydro-1H-imidazol-2-yl]benzene is a major product (mp
301–303°C). Application of the fusion reaction (below) with ethylenediamine hydrochloride
for disubstituted triazines leads to the same undesired product [27]. 1H-NMR (DMSO-d6,
TMS) δ 3.65 (s, 8H), 6.71 (br s, 2H), 7.84 (s, 4H). 13C-NMR (CD3COOD, TMS), δ 46.1,
128.4, 130.5, 166.2. IR (KBr), ν 3175, 2927, 2862, 1603, 1524, 1485, 1461, 1342, 1307,
1271 cm−1. MS, m/z: 214 (M+).
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A mixture of 1,4-dicyanobenzene (25.6 g, 0.2 mol), 1,1-dimethylguanidine sulfate (13.6 g,
0.05 mol), sodium hydride (8.0 g of 60% oil dispersion, 0.2 mol), and N,N-
dimethylformamide (200 mL) was stirred first at 0°C and then at room temperature for 3 h.
After heating at 75°C for 3 h (TLC (CHCl3) showed the absence of 1,4-dicyanobenzene),
the solvent was evaporated under vacuum and water (100 mL) was added. The solid was
filtered, washed with water and methanol, subjected to silica-gel column chromatography,
and eluted with chloroform. The eluent on concentration and addition of ethanol gave
analytically pure bis-nitrile. The product can be recrystallized from pyridine. Yield, 8.7 g
(27%), mp 264°C. Anal calc C19H14N6: C, 69.92; H, 4.32; N, 25.76; found: C, 69.85; H,
4.31; N, 25.78. 1H-NMR (DMSO-d6, TMS), δ 3.34 (s, 6H), 8.01 (d, 4H, J = 8.3 Hz), 8.65
(d, 4H. J = 8.3 Hz). 13C-NMR (DMSO-d6, TMS), δ 36.1, 114.3, 118.3, 128.8, 132.5, 140.2,
164.8. 168.7. IR (KBr): ν 2228, 1593, 1507, 1382, 1003, 810, 549 cm−1. MS, m/z: 326.
4,6-Bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-2-dimethylamino-1,3,5-triazine
dihydrochloride dihydrate 9a
A mixture of the above bis-nitrile (2 g, 6 mmol), ethylenediamine dihydrochloride (8.2 g,
0.06 mol), and ethylenediamine (4.1 mL, 0.06 mol) was maintained in a sand-bath at 300–
310°C for 10 min, during which time ammonia was evolved. The crude product was
dissolved in hot water and a brown solid was filtered and discarded; crystals separated on
cooling the filtrate. After recrystallization from boiling water chromatographically pure
product was collected, washed with cold water, and dried overnight in a vacuum oven at
70°C. The product (0.95 g, 30%) did not melt at temperatures up to 360°C. Anal calc
C23H24N8·2HCl·2H2O; C, 52.98; H, 5.80; N, 21.49; found: C, 53.00; H, 5.82; N, 21.39. 1H-
NMR (DMSO-d6, TMS), δ 3.38 (s, 6H), 4.06 (s, 8H), 8.17 (d, 4H, J = 8.3 Hz), 8.76 (d, 4H,
J = 8.3 Hz), 10.75 (brs, 4H). 13C-NMR (D2O, (CH3)3SiCH2CH2COONa), δ 37.1, 46.0,
125.0, 129.1, 130.2, 142.4, 165.3, 166.0, 169.4. IR (KBr): ν 3418, 3086, 2954, 1581, 1506,
1384, 1286, 1001, 816 cm−1. MS, (free base) m/z: 412 (M+).
2-Dimethylamino-4,6-bis[4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]-1,3,5-triazine
dihydrochloride dihydrate 9b
This compound was prepared from the above bis-nitrile (2 g, 6 mmol) 1,3-diaminopropane
dihydrochloride (9.0 g, 0.06 mol) and 1,3-diaminopropane (5.1 mL, 0.06 mol) as described
for the imidazoline derivative. The hydrochloride was sparingly soluble in water and it was
preferable to liberate the base from the reaction mixture by means of 1 N sodium hydroxide
solution (50 mL). The crude base (1.54 g, 57%) was filtered, washed with water and
crystallized from ethanol/acetone/water solution. The purified base (mp 303–305°C) was
converted into the hydrochloride by means of hydrogen chloride in ethanol and then
precipitated with ethyl ether. Yield, 1.1 g (32%). The product did not melt at temperatures
up to 360°C. Anal calc C25H28N8·2HCl·2H2O: C, 54.64; H, 6.24; N, 20.40; found: C, 54.74;
H, 6.23; N, 20.33. 1H-NMR (DMSO-d6, TMS), δ 2.02 (brt, 4H), 3.42 (s, 6H), 3.54 (brt, 8H),
8.04 (d, 4H, J = 8.3 Hz), 8.61 (d, 4H, J = 8.3 Hz), 10.54 (brs, 4H). 13C-NMR (DMSO-d6,
TMS), δ 17.5, 36.0, 38.6, 128.0, 128.4, 131.1, 140.0, 158.3, 164.6, 168.7. IR (KBr): ν 3416,
3146, 2995, 1644, 1588, 1534, 1507, 1374, 1316, 1202, 1002, 815 cm−1. MS (free base), m/
z: 440 (M+).
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a) Formamidine hydrochloride, 190°C; b) CuCN, quinoline, reflux; c) POCl3, reflux; d)
H2S, ethylenediamine or 1,3-diaminopropane, dimethoxyethane, reflux.
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a) 1,1-Dimethylguanidine sulfate, NaH, DMF; b) ethylenediamine or 1,3-diaminopropane
hydrochloride.
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